Tarsus Pharmaceuticals Q4 EPS $(0.20) Misses $(0.11) Estimate, Sales $151.668M Beat $144.565M Estimate
Benzinga Newsdesk 8 months ago
EarningsEarnings BeatsEarnings MissesNews
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.11) by 81.82 percent. This is a 66.67 percent increase over losses of $(0.60) per
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.11) by 81.82 percent. This is a 66.67 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $151.668 million which beat the analyst consensus estimate of $144.565 million by 4.91 percent. This is a 128.39 percent increase over sales of $66.408 million the same period last year.